• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Baxter International Inc.

    4/29/26 8:30:43 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care
    Get the next $BAX alert in real time by email
    DEFA14A 1 d138472ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No. )

     

     

    Filed by the Registrant ☑

    Filed by a Party other than the Registrant ☐

    CHECK THE APPROPRIATE BOX:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☑

    Definitive Additional Materials

     

    ☐

    Soliciting Material Under Rule 14a-12

     

    LOGO

    Baxter International Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

    PAYMENT OF FILING FEE (CHECK THE APPROPRIATE BOX):

     

    ☑

    No fee required.

     

    ☐

    Fee paid previously with preliminary materials:

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

    April 29, 2026

     

     
     


    Dear Fellow Stockholders,

    We are writing today to request your support for our proposal to amend Baxter’s Certificate of Incorporation (Proposed Charter Amendment) to reduce the minimum number of directors from nine to seven and eliminate the maximum number of directors, with the exact number to be fixed from time to time by the Board. In response to investor feedback on this proposal, the Board has also adopted an amendment to the Company’s Bylaws (Bylaws Amendment), fixing the Board size within a range of seven to twelve members and retaining clear parameters consistent with prevailing governance practices. The Bylaws Amendment takes effect only if stockholders approve the Proposed Charter Amendment and is subject to its terms.

    We believe the combination of the Proposed Charter Amendment and Bylaws Amendment creates a framework that provides the following benefits and is in the best interests of Baxter and its stockholders:

     

      •  

    Flexible Framework: It preserves the Board’s ability to adjust its size as circumstances warrant while maintaining the optimal number of directors to facilitate effective decision making.

     

      •  

    Supportive of Future Board Refreshment: It is intended to preserve flexibility for continuing Board refreshment and thoughtful succession planning, ensuring an optimal mix of skills, perspectives and experiences on the Board.

     

      •  

    Clearly Defined Guardrails: It provides stockholders with assurance that any changes to Board size will continue to occur within clear and disciplined parameters, which the Board intends to maintain in the Bylaws until the next Charter amendment is approved by stockholders (at which time the related range would be moved to the Charter).

    The Board reiterates its recommendation to vote “FOR” the Proposed Charter Amendment.

    We encourage you to review the Proxy Statement and consider this supplemental information in connection with your vote at the Annual Meeting. If you have already voted Against the Proposed Charter Amendment, you may change your vote by following the instructions included in the Proxy Statement.

    This Supplement should be read in conjunction with the Proxy Statement. Except as described above, this Supplement does not amend, supplement, or otherwise affect the Proxy Statement.

    Thank you for your continued investment and support of Baxter International Inc.

     

    Sincerely,

     

    /s/ Brent Shafer

     

    Brent Shafer
    Non-Executive Chair of the Board
    Get the next $BAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BAX

    DatePrice TargetRatingAnalyst
    5/28/2026$17.00Neutral → Sell
    Citigroup
    10/31/2025Buy → Hold
    Argus
    8/4/2025$25.00Buy → Hold
    Stifel
    8/1/2025$25.00Buy → Neutral
    Goldman
    2/26/2025$42.00Buy
    Goldman
    2/24/2025Hold → Buy
    Argus
    2/20/2025$39.00Overweight
    Barclays
    7/15/2024$39.00 → $30.00Equal-Weight → Underweight
    Morgan Stanley
    More analyst ratings

    $BAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Baxter downgraded by Citigroup with a new price target

    Citigroup downgraded Baxter from Neutral to Sell and set a new price target of $17.00

    5/28/26 8:45:02 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Argus

    Argus downgraded Baxter from Buy to Hold

    10/31/25 8:47:22 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter downgraded by Stifel with a new price target

    Stifel downgraded Baxter from Buy to Hold and set a new price target of $25.00

    8/4/25 8:18:58 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    4D Path Announces Strategic Financing and Appointment of Katherine Vega Stultz and Robert J. Hombach to Its Board of Directors

    Financing to accelerate 4D Path's pipeline of treatment predictive biomarkers in solid tumors. 4D Path adds two seasoned healthcare executives to strengthen its board and accelerate growth. Ms. Stultz to serve as 4D Path Board Chair 4D Path, a company dedicated to personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy, today announced the first close of a strategic financing round to accelerate the development of treatment predictive biomarkers for 4D Path-sponsored clinical use and partnerships with Biopharma companies. 4D Path's strategy is to develop digital treatment prediction biomarkers that inform more clear and accurate treatmen

    5/5/26 7:00:00 AM ET
    $BAX
    $BMRN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Baxter Reports First-Quarter 2026 Results

    Sales from continuing operations of $2.7 billion increased 3% on a reported basis and declined 1% on an organic basis1,2 U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.03); adjusted diluted EPS from continuing operations of $0.36 Reiterates full-year 2026 financial outlook Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2026. "Financial results for the quarter overall were in line with our expectations, and we are making progress to stabilize the business, embed a culture of continuous improvement, and strengthen execution," said Andrew Hider, president and CEO. "Although more wo

    4/30/26 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Showcases Recent Innovations at AORN Global Surgical Conference & Expo 2026

    Highlights include the AAT XR, the next-generation version of the Allen Advance Table designed to support surgical teams across a range of spine procedures, and the Dynamo Series smart stretcher Baxter International Inc. (NYSE:BAX), a global medtech leader, is highlighting recent additions to its Global Surgical Solutions and Patient Support Systems portfolios, as well as its broad Advanced Surgery portfolio of hemostatic and sealing agents, at the Association of periOperative Registered Nurses (AORN) Global Surgical Conference & Expo, taking place April 11-14, 2026 in New Orleans. New offerings include the AAT XR spine surgical table and the Dynamo Series smart stretcher, both on display

    4/13/26 9:00:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SVP, Interim CFO, CAO & Cntrlr Zielinski Anita A was granted 13,426 shares, increasing direct ownership by 29% to 59,714 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    6/3/26 4:07:23 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    President, Adv. Surgery Wallace Steven P. covered exercise/tax liability with 153 shares, decreasing direct ownership by 0.22% to 70,128 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    6/3/26 4:06:38 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    President, CCS Teaff James covered exercise/tax liability with 321 shares, decreasing direct ownership by 1% to 31,063 units (SEC Form 4)

    4 - BAXTER INTERNATIONAL INC (0000010456) (Issuer)

    6/3/26 4:05:30 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    SEC Filings

    View All

    SEC Form SD filed by Baxter International Inc.

    SD - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    5/29/26 8:28:26 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Baxter International Inc.

    S-8 - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    5/8/26 5:11:30 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter International Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

    8-K - BAXTER INTERNATIONAL INC (0000010456) (Filer)

    5/8/26 4:16:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Baxter International Inc.

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    11/13/24 1:08:27 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Baxter International Inc. (Amendment)

    SC 13G/A - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 5:00:53 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Baxter International Inc.

    SC 13G - BAXTER INTERNATIONAL INC (0000010456) (Subject)

    2/13/24 1:08:57 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Financials

    Live finance-specific insights

    View All

    Baxter Reports First-Quarter 2026 Results

    Sales from continuing operations of $2.7 billion increased 3% on a reported basis and declined 1% on an organic basis1,2 U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($0.03); adjusted diluted EPS from continuing operations of $0.36 Reiterates full-year 2026 financial outlook Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the first quarter of 2026. "Financial results for the quarter overall were in line with our expectations, and we are making progress to stabilize the business, embed a culture of continuous improvement, and strengthen execution," said Andrew Hider, president and CEO. "Although more wo

    4/30/26 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter to Host First-Quarter 2026 Financial Results Conference Call for Investors

    Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its first-quarter 2026 financial results on Thursday, April 30, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I946023356 to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.com. The conference call will be recorded by Baxter and is copyrighted material. It cannot be recorded or rebroadcast without Baxter's permission. About Baxter At Baxter, we are everywhere healthcare happens – and everyw

    4/8/26 4:15:00 PM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    Baxter Reports Fourth-Quarter 2025 Results

    Fourth-quarter sales from continuing operations of $2.97 billion increased 8% on a reported basis and 3% on an operational basis1,2 Fourth-quarter U.S. GAAP3 diluted earnings per share (EPS) (loss) from continuing operations of ($2.01); adjusted diluted EPS from continuing operations of $0.44 Company advances ongoing board of directors refreshment Baxter International Inc. (NYSE:BAX), a global medtech leader, today reported results for the fourth quarter of 2025. "While we delivered sales growth across all segments, our fourth-quarter results did not meet our expectations, underscoring the importance of our focus on driving continuous improvement across the enterprise," said And

    2/12/26 7:15:00 AM ET
    $BAX
    Medical/Dental Instruments
    Health Care

    $BAX
    Leadership Updates

    Live Leadership Updates

    View All

    4D Path Announces Strategic Financing and Appointment of Katherine Vega Stultz and Robert J. Hombach to Its Board of Directors

    Financing to accelerate 4D Path's pipeline of treatment predictive biomarkers in solid tumors. 4D Path adds two seasoned healthcare executives to strengthen its board and accelerate growth. Ms. Stultz to serve as 4D Path Board Chair 4D Path, a company dedicated to personalizing cancer care through a novel, physics-informed approach to predict tumor response to therapy, today announced the first close of a strategic financing round to accelerate the development of treatment predictive biomarkers for 4D Path-sponsored clinical use and partnerships with Biopharma companies. 4D Path's strategy is to develop digital treatment prediction biomarkers that inform more clear and accurate treatmen

    5/5/26 7:00:00 AM ET
    $BAX
    $BMRN
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Baxter Appoints Andrew Hider Chief Executive Officer

    Baxter International Inc. (NYSE:BAX), a global medtech leader, today announced the appointment of Andrew Hider as president and chief executive officer (CEO), and a member of its board of directors. Mr. Hider will assume his responsibilities at Baxter no later than Sept. 3, 2025, or an earlier date pending completion of his current employment commitments. Brent Shafer, who has served as chair and interim CEO since February 2025, will then transition to independent chair of the Baxter Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250706840140/en/Andrew Hider Appointed Baxter's Next CEO Since 2017, Mr. Hider has served as

    7/7/25 8:35:00 AM ET
    $ATS
    $BAX
    Industrial Machinery/Components
    Industrials
    Medical/Dental Instruments
    Health Care

    Amerant Bancorp Announces Appointment of Two New Board Members

    Amerant Bancorp Inc. (NYSE:AMTB) ("Amerant" or "the Company") and its subsidiary, Amerant Bank, N.A. (the "Bank"), today announced the appointment of two accomplished executives, Patricia "Patty" Morrison and Jack Kopnisky, to the Board of Directors of the Company and the Bank. Their addition reflects the Company's continued commitment to strategic growth and further strengthening of the Board of Directors and executive management. "We are delighted to welcome both Patty and Jack to our Board of Directors," said Jerry Plush, Chairman and CEO of Amerant and the Bank. "Patty's deep technology leadership and extensive board expertise, paired with Jack's enviable experience in leading high pe

    6/24/25 9:20:00 AM ET
    $AMTB
    $BAX
    $WBS
    Major Banks
    Finance
    Medical/Dental Instruments
    Health Care